Lumosa Therapeutics: The Board of Directors Approved the 2021 Consolidated Financial Report

0






Close

Supplied by: LUMOSA THERAPEUTICS CO., LTD.

SEQ_NO

4

announcement date

2022/03/04

Announcement time

16:30:43

Topic

 LUMOSA Board of Directors approved the 2021
consolidated financial report

Date of events

2022/03/04

What item it responds to

paragraph 31

Declaration

1.Date of the board of directors submitted or approved:2022/03/04
2.Date of the audit committee approved:2022/03/04
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2021/01/01~2021/12/31
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):17,362
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):9,889
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(430,278)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):95,946
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):95,946
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):95,946
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):0.64
11.Total assets end of the period (thousand NTD):2,348,695
12.Total liabilities end of the period
(thousand NTD):230,108
13.Equity attributable to owners of parent end of the
period (thousand NTD):2,118,587
14.Any other matters that need to be specified:NA

Warning

Lumosa Therapeutics Co. Ltd. published this content on March 04, 2022 and is solely responsible for the information contained therein. Distributed by publicunedited and unmodified, on March 04, 2022 08:45:02 UTC.

Public now 2022

All news about LUMOSA THERAPEUTICS CO., LTD.

Sales 2021 30.0 million
1.06M
1.06M
Net income 2021

Net debt 2021

PER 2021 ratio
2021 performance
Capitalization 6,110M
217M
217M
capi. / Sales 2021 204x
capi. / Sales 2022 118x
# of employees 43
Floating 48.2%

Chart LUMOSA THERAPEUTICS CO., LTD.


Duration :

Period :




Lumosa Therapeutics Co., Ltd. Technical Analysis Chart  |  MarketScreener



Evolution of the income statement

To sell

To buy

Medium consensus SURPASS
Number of analysts 1
Last closing price

TWD37.45

Average target price

TWD50.00

Average Spread / Target 33.5%


Share.

Comments are closed.